These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 8496760)
1. Hyperimmune human IgG or recombinant human granulocyte-macrophage colony-stimulating factor as adjunctive therapy for group B streptococcal sepsis in newborn rats. Givner LB; Nagaraj SK J Pediatr; 1993 May; 122(5 Pt 1):774-9. PubMed ID: 8496760 [TBL] [Abstract][Full Text] [Related]
2. Prophylactic or simultaneous administration of recombinant human granulocyte colony stimulating factor in the treatment of group B streptococcal sepsis in neonatal rats. Cairo MS; Mauss D; Kommareddy S; Norris K; van de Ven C; Modanlou H Pediatr Res; 1990 Jun; 27(6):612-6. PubMed ID: 1694023 [TBL] [Abstract][Full Text] [Related]
3. Pooled human IgG hyperimmune for type III group B streptococci: evaluation against multiple strains in vitro and in experimental disease. Givner LB; Baker CJ J Infect Dis; 1991 May; 163(5):1141-5. PubMed ID: 2019763 [TBL] [Abstract][Full Text] [Related]
4. Effect of recombinant human granulocyte colony-stimulating factor administration in normal and experimentally infected newborn rats. Iguchi K; Inoue S; Kumar A Exp Hematol; 1991 Jun; 19(5):352-8. PubMed ID: 1709109 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic use of recombinant human granulocyte-macrophage colony-stimulating factor in neonatal rats with type III group B streptococcal sepsis. Wheeler JG; Givner LB J Infect Dis; 1992 May; 165(5):938-41. PubMed ID: 1533238 [TBL] [Abstract][Full Text] [Related]
6. Antibodies to tumor necrosis factor-alpha: use as adjunctive therapy in established group B streptococcal disease in newborn rats. Givner LB; Gray L; O'Shea TM Pediatr Res; 1995 Oct; 38(4):551-4. PubMed ID: 8559608 [TBL] [Abstract][Full Text] [Related]
7. Failure of gamma-interferon to decrease mortality from group B streptococcal sepsis in neonatal rats. Wittler RR; Harris RW; Paine DD Biol Neonate; 1999 Aug; 76(2):125-8. PubMed ID: 10393998 [TBL] [Abstract][Full Text] [Related]
8. A polyclonal human IgG preparation hyperimmune for type III, group B Streptococcus: in vitro opsonophagocytic activity and efficacy in experimental models. Givner LB; Edwards MS; Baker CJ J Infect Dis; 1988 Oct; 158(4):724-30. PubMed ID: 3049837 [TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin therapy of neonatal group B streptococcal infections: an overview. Fischer GW Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S13-6. PubMed ID: 3041355 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of human immunoglobulin and penicillin G in treatment of experimental group B streptococcal infection. Kim KS Pediatr Res; 1987 Mar; 21(3):289-92. PubMed ID: 3550675 [TBL] [Abstract][Full Text] [Related]
11. High intravenous doses of human immune globulin suppress neonatal group B streptococcal immunity in rats. Weisman LE; Lorenzetti PM J Pediatr; 1989 Sep; 115(3):445-50. PubMed ID: 2671331 [TBL] [Abstract][Full Text] [Related]
12. Comparison of group B streptococcal hyperimmune globulin and standard intravenously administered immune globulin in neonates. Weisman LE; Anthony BF; Hemming VG; Fischer GW J Pediatr; 1993 Jun; 122(6):929-37. PubMed ID: 8501574 [TBL] [Abstract][Full Text] [Related]
13. Impaired phagocytosis and opsonisation towards group B streptococci in preterm infants. Jaswon MS; Katz DR Arch Dis Child Fetal Neonatal Ed; 1999 Mar; 80(2):F160. PubMed ID: 10325802 [No Abstract] [Full Text] [Related]
14. Potential use of intravenous immune globulin for group B streptococcal infection. Baker CJ; Noya FJ Rev Infect Dis; 1990; 12 Suppl 4():S476-82. PubMed ID: 2194272 [TBL] [Abstract][Full Text] [Related]
15. Polyvalent group B streptococcal immune globulin for intravenous administration: overview. Fischer GW; Hemming VG; Gloser HP; Bachmayer H; von Pilar CE; Wilson SR; Baron PA Rev Infect Dis; 1990; 12 Suppl 4():S483-9; discussion S489-91. PubMed ID: 2194273 [TBL] [Abstract][Full Text] [Related]
17. Effect of antimicrobial therapy for experimental infections due to group B Streptococcus on mortality and clearance of bacteria. Kim KS J Infect Dis; 1987 Jun; 155(6):1233-41. PubMed ID: 3553349 [TBL] [Abstract][Full Text] [Related]
18. Endogenous interleukin-11 (IL-11) expression is increased and prophylactic use of exogenous IL-11 enhances platelet recovery and improves survival during thrombocytopenia associated with experimental group B streptococcal sepsis in neonatal rats. Chang M; Williams A; Ishizawa L; Knoppel A; van de Ven C; Cairo MS Blood Cells Mol Dis; 1996; 22(1):57-67. PubMed ID: 8807086 [TBL] [Abstract][Full Text] [Related]
19. Recent developments and current issues in the epidemiology, diagnosis, and management of bacterial and fungal neonatal sepsis. Shane AL; Stoll BJ Am J Perinatol; 2013 Feb; 30(2):131-41. PubMed ID: 23297182 [TBL] [Abstract][Full Text] [Related]
20. Rifampin and penicillin for the elimination of group B streptococci in nasally colonized infant rats. Millard DD; Shulman ST; Yogev R Pediatr Res; 1985 Nov; 19(11):1183-6. PubMed ID: 3906547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]